Inhibrx Biosciences (INBX) said late Tuesday that Brendan Eckelman, its co-founder and chief scientific officer, will leave the company to form a private biotechnology firm that signed an exclusive license agreement with Inhibrx.
The deal is for the rights to certain technologies no longer being pursued by Inhibrx. The pact includes an upfront payment upon completion of the initial funding of Eckelman's new company and other future development milestones.
Carlos Bais, Inhibrx's executive vice president of translational sciences, will be appointed chief scientific officer and David Matly will become president, in addition to his existing role as chief commercial and business development officer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。